J&J’s Tecvayli/Darzalex nod is the second under a new priority voucher scheme.
ApexOnco Front Page
Recent articles
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
The company is set to start a phase 2/3 trial this month.
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Global phase 2 data in TNBC look similar to earlier results in China.
